GSK, Genmab Had Hoped For An Arzerra Indication With More Bulk
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline and Genmab gambled that by submitting a pivotal trial including both chronic lymphocytic leukemia patients refractory to two standard therapies and patients refractory to only one of them, fludarabine, but who also had bulky lymphadenopathy, they could garner a broader indication for Arzerra (ofatumumab), despite advice from FDA that the two groups could not be combined for one indication
You may also be interested in...
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.